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Abstract 
A 75-year-old man underwent endoscopic hemostatic therapy for hemorrhagic gastric 
ulcer in September 2002. After healing of the gastric ulcer, he underwent Helicobacter 
pylori eradication therapy in February 2003. In August 2007, an irregular tumor was 
detected in the lower esophagus at annual checkup for gastric cancer screening using 
X-ray. Endoscopic examination showed that the lower margin of the tumor almost 
coincided with the esophagogastric junction and that a short segment of Barrett’s 
epithelium existed near the tumor. Biopsies of the tumor showed moderately to poorly 
differentiated adenocarcinoma. Mild reflux esophagitis and minor hiatal hernia was also 
observed, and the previously treated gastric ulcer was not recurrent. Absence of H. pylori 
was confirmed by serum antibody and urea breath test. Surgical resection of the lower 
esophagus and proximal stomach was performed. The tumor invaded into the muscularis 
propria of the esophageal wall but had no evidence of lymph node metastasis. Based on 
macroscopic and pathological findings, the tumor was recognized as esophageal 
adenocarcinoma. Previous endoscopic examination did not detect any apparent signs of 
tumor in the esophagogastric junction. As far as we know, this is the first report 
documenting a newly developed esophageal adenocarcinoma after the successful 
eradication of H. pylori. Case Rep Gastroenterol 2011;5:355–360 
DOI: 10.1159/000329878 
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Introduction 
Previous reports have demonstrated that Helicobacter pylori infection is significantly 
less prevalent in patients with gastroesophageal reflux disease (GERD) compared to 
control subjects without GERD, indicating that H. pylori infection has a potentially 
protective role in the development of GERD [1]. This protective role is cancelled by the 
successful eradication of H. pylori, which can lead to an increase in newly developing 
GERD at least in some areas such as Asian countries [2–6]. GERD is a well-known risk 
factor for complications such as Barrett’s esophagus or esophageal adenocarcinoma [7], 
so there has been concern that the de novo development and the persistence of GERD 
after H. pylori eradication may result in increased risk for esophageal adenocarcinoma. 
Until now, the long-term course of newly developing GERD after H. pylori eradication 
remains unknown, and there has been no report documenting a case who developed 
esophageal adenocarcinoma after eradication therapy. Herein we report the first case of 
esophageal adenocarcinoma developing after H. pylori eradication. 
Case Report 
A 75-year-old man underwent endoscopic hemostatic therapy (pure ethanol injection method) for 
hemorrhagic gastric ulcer of the gastric body in September 2002. After healing of the gastric ulcer, the 
patient was diagnosed to be infected with H. pylori by serum antibody and urea breath test. H. pylori 
eradication therapy was performed using lansoprazole 30 mg, amoxicillin 750 mg and clarithromycin 
200 mg twice daily for a week in February 2003. Eradication was confirmed successful by urea breath 
test, and he was able to cease taking regular medication in August 2003.  
In August 2007, he underwent an examination for gastric cancer screening using X-ray. An irregular 
tumor approximately 3 cm in diameter was detected in the lower esophagus, so he consulted our 
hospital for further examination and treatment. He had neither had any upper abdominal symptoms 
nor acid-suppressive therapy since the previous treatment for gastric ulcer. Endoscopic examination 
showed that the tumor was located in the 1 o’clock position of the lower end of the esophagus (fig. 1a), 
and the lower margin of the tumor almost coincided with the esophagogastric junction (fig. 1b). A short 
segment of columnar-lined esophagus with squamous islands (short-segment Barrett’s epithelium) was 
observed in the 11 o’clock position of the esophagogastric junction near the tumor (fig. 1c). Biopsies of 
the tumor showed moderately to poorly differentiated adenocarcinoma. Mild reflux esophagitis 
corresponding to Los Angeles grade A, minor hiatal hernia and scarring from the previously treated 
gastric ulcer were also present. Absence of H. pylori was confirmed by serum antibody and urea breath 
test.  
Surgical resection of the lower esophagus and the proximal stomach was performed in November 
2007. In the resected samples, the tumor was localized in the lower end of the esophagus as observed by 
endoscopy (fig. 2a). Pathological examination showed that the tumor invaded into the muscularis 
propria of the esophageal wall but had no evidence of lymph node metastasis. Intestinal metaplasia and 
submucosal esophageal glands were histologically confirmed in the coexistent short segment of Barrett’s 
epithelium near the tumor (fig. 2b). Retrospective assessment of previous endoscopic examination 
performed in December 2002 prior to eradication therapy did not show any apparent signs of tumor in 
the lower esophagus (fig. 3). Thus, the tumor was considered as a newly developed esophageal 
adenocarcinoma after the successful eradication of H. pylori. 
Discussion 
In this case report, we describe a male patient with newly developed esophageal 
adenocarcinoma discovered 5 years after the eradication of H. pylori. No evidence of this Case Rep Gastroenterol 2011;5:355–360 
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tumor was found in the previous endoscopic examination performed before and 
immediately after eradication therapy. 
Labenz et al. [8] previously reported an alarming observation that reflux esophagitis 
newly developed in up to 26% of patients with duodenal ulcer after the clearance of 
H. pylori, whereas it was present only in 13% of those with persistent infection. Barrett’s 
esophagus and adenocarcinoma related to it have been recognized as a complication of 
GERD [7], so their report raised a special concern that H. pylori eradication therapy 
may be a potential risk factor for developing esophageal adenocarcinoma. Thus far, 
there has been no report documenting newly developed esophageal adenocarcinoma 
after eradication therapy. Although many studies have been conducted to address 
the relation between GERD and H. pylori eradication, whether or not GERD can be 
significantly increased or exacerbated after H. pylori eradication is still controversial, 
probably due to the demographic or geographic differences or varying follow-up 
periods in the previous studies [9]. However, in Asian countries such as Japan or Korea, 
it has been consistently reported that eradication therapy significantly increases the risk 
for newly developing erosive esophagitis [2–6]. There is also an intriguing case report 
by Kokkola et al. [10], who described a patient having a 3-cm-long Barrett’s epithelium 
through erosive esophagitis 5 years after spontaneous clearance of H. pylori. 
In the current case, when esophageal adenocarcinoma was discovered, mild erosive 
esophagitis and hiatal hernia were concurrently present, although those findings 
were secondarily induced by the development of the tumor. In addition, coexistent 
short-segment Barrett’s epithelium seen in the 11 o’clock position of the esophagogastric 
junction was likely to have increased its length with some squamous islands when the 
endoscopic views before and after eradication therapy were compared retrospectively. 
These observations imply that GERD was exacerbated after the successful eradication of 
H. pylori in our patient. Gastric acid is one of the most critically causative factors in the 
reflux materials for esophageal mucosal injury in GERD. As we and other investigators 
have reported, the recovery of gastric acid secretion after eradication is the key pathogenic 
factor for newly developing erosive esophagitis in addition to individual predisposition 
to gastroesophageal reflux such as hiatal hernia, male sex or increased body mass index 
[2–6, 11]. Based on our previous report showing that gastric acid secretion significantly 
increases after cure of H. pylori infection in patients with gastric ulcer [12], the acidity 
of gastric acid was probably increased after eradication therapy as well in the present 
patient, who also suffered from gastric ulcer. Thus, it is conceivable that our patient 
would be the first case who newly developed esophageal adenocarcinoma through GERD 
after eradication therapy. The involvement of refluxed gastric acid in the carcinogenesis 
of Barrett’s esophagus has been supported by previous in vitro and ex vivo studies, which 
have demonstrated that abnormal esophageal acid exposure can increase proliferation or 
cause DNA injury in Barrett’s epithelium [13]. 
Successful eradication of H. pylori has many advantages in preventing the relapse of 
gastroduodenal ulcer, leading mucosa-associated lymphoid tissue lymphoma to remission 
status, or reducing the risk of gastric cancer [14]. On the other hand, newly developed 
GERD or erosive esophagitis have been reported as a potential disadvantage of H. pylori 
eradication therapy, but the majority of those conditions after eradication have been 
reported to be mild and not progressively exacerbated for several years [15]. Therefore, a 
potentially increased risk of GERD after H. pylori eradication therapy should not preclude 
the practice of eradication therapy. However, as suggested in this case report, further Case Rep Gastroenterol 2011;5:355–360 
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long-term follow-up will be needed in consideration of the emergence of GERD and its 
subsequent complications including esophageal cancer even in subjects with successful 
eradication of H. pylori. 
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Fig. 1. a Endoscopic image of the lower esophagus. The tumor was found to be located in the 1 o’clock 
position of the lower end of the esophagus. b Endoscopic image of the esophagogastric junction. The 
lower margin of the tumor almost coincided with the esophagogastric junction. c Endoscopic image of 
the tumor and the short segment of Barrett’s epithelium. A short segment of columnar lined esophagus 
with squamous islands (short-segment Barrett’s epithelium) was observed in the 11 o’clock position of 
the esophagogastric junction near the tumor (arrows). 
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Fig. 2. a Gross image of the resected sample. The tumor was mostly localized proximally to the 
esophagogastric junction and the cardiac notch, which is presumptively depicted by the broken line and 
the white arrows, respectively. b Close-up image around the esophagogastric junction. As seen in 
endoscopy, short-segment Barrett’s epithelium was observed near the tumor (black arrows), with 
intestinal metaplasia and submucosal esophageal glands histologically confirmed. 
 
 
 
Fig. 3. Endoscopic image of the esophagogastric junction in December 2002. No apparent evidence of 
tumor in the lower esophagus was found in the previous endoscopic examination prior to eradication 
therapy. 
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